Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potential role of antioxidants in the treatment of portal hypertension.

Literature DB >> 17161493

Potential role of antioxidants in the treatment of portal hypertension.

Aina Rodríguez-Vilarrupla¹, Jaume Bosch, Joan-Carles García-Pagán.

Abstract

Entities: Disease

Mesh：

Substances：
Antioxidants

Year: 2006 PMID： 17161493 DOI： 10.1016/j.jhep.2006.11.008

Source DB: PubMed Journal: J Hepatol ISSN： 0168-8278 Impact factor: 25.083

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

1. Relevance of plasma malondialdehyde level and severity of portal hypertension in cirrhotic patients.

Authors: Sheng-Lan Wang; Xin-Yan Zhu; Dong-Wei Zhang; Zhao-Jie Zhang; Heng-Jun Gao; Chang-Qing Yang
Journal: Int J Clin Exp Med Date: 2015-07-15

2. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure.

Authors: Kuei-Chuan Lee; Ying-Ying Yang; Ying-Wen Wang; Fa-Yauh Lee; Che-Chuan Loong; Ming-Chih Hou; Han-Chieh Lin; Shou-Dong Lee
Journal: Dig Dis Sci Date: 2009-10-14 Impact factor: 3.199

3. N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive rats.

Authors: Francielli Licks; Renata Minuzzo Hartmann; Camila Marques; Elizângela Schemitt; Josieli Raskopf Colares; Mariana do Couto Soares; Juliana Reys; Camila Fisher; Juliana da Silva; Norma Possa Marroni
Journal: World J Gastroenterol Date: 2015-11-21 Impact factor: 5.742

Review 4. Inflammation: a way to understanding the evolution of portal hypertension.

Authors: María-Angeles Aller; Jorge-Luis Arias; Arturo Cruz; Jaime Arias
Journal: Theor Biol Med Model Date: 2007-11-13 Impact factor: 2.432

5. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

Authors: Sarai Rodríguez; Imma Raurell; Manuel Torres-Arauz; Teresa García-Lezana; Joan Genescà; María Martell
Journal: Sci Rep Date: 2017-01-13 Impact factor: 4.379

Potential role of antioxidants in the treatment of portal hypertension.

1. Relevance of plasma malondialdehyde level and severity of portal hypertension in cirrhotic patients.

2. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure.

3. N-acetylcysteine modulates angiogenesis and vasodilation in stomach such as DNA damage in blood of portal hypertensive rats.

Review 4. Inflammation: a way to understanding the evolution of portal hypertension.

5. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

6. Glutamine prevents oxidative stress in a model of portal hypertension.

7. Novel treatment options for portal hypertension.

Review 8. The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension.

Review 9. The Endothelium as a Driver of Liver Fibrosis and Regeneration.